A clear, clinically grounded guide to understanding autologous stem cell transplantation as a treatment for multiple myeloma — and how to know if you or a loved one may be a candidate.
By the Apex Hospitals Editorial Team · Published July 2025
Multiple myeloma is a cancer of plasma cells — the white blood cells in bone marrow responsible for producing antibodies. When these cells multiply uncontrollably, they crowd out healthy blood cells, weaken bones, impair kidney function, and suppress the immune system. It is the second most common blood cancer worldwide, and according to the World Health Organization, haematological malignancies like myeloma are rising in incidence across South Asia.
In India, multiple myeloma accounts for roughly 10–15% of all haematological cancers. The disease is more common in adults over 60, though younger patients are increasingly diagnosed. Treatment has advanced dramatically over the past two decades — and for eligible patients, autologous stem cell transplantation (ASCT) remains one of the most effective strategies to achieve deep remission and extend survival.
The haemato-oncology team at Apex Hospitals in Jaipur manages the full spectrum of blood cancers, including multiple myeloma, with access to bone marrow transplant protocols and modern induction regimens.
An autologous stem cell transplant (also called an autologous bone marrow transplant or auto-BMT) uses the patient's own stem cells, collected before high-dose chemotherapy is administered. Here is how the process works:
Induction therapy: The patient first receives 3–6 cycles of combination chemotherapy (commonly VRd — bortezomib, lenalidomide, dexamethasone) to reduce the myeloma burden.
Stem cell mobilisation and collection: Growth factors (G-CSF) stimulate the bone marrow to release stem cells into the bloodstream. These are harvested via apheresis — a process similar to dialysis — and frozen for storage.
High-dose chemotherapy (conditioning): A high dose of melphalan is administered to destroy remaining myeloma cells in the bone marrow.
Stem cell infusion: The stored stem cells are thawed and infused back into the patient, where they migrate to the bone marrow and rebuild a healthy blood system over 2–4 weeks.
Engraftment and recovery: Blood counts recover, and the patient is monitored closely for infection, mucositis, and other side effects during the engraftment phase.
Unlike allogeneic transplants (which use a donor's cells), autologous transplants carry a lower risk of graft-versus-host disease, making them the standard approach for myeloma in transplant-eligible patients.
Not every myeloma patient requires a transplant. The decision depends on several clinical and patient-specific factors. Broadly, haematologists consider ASCT when:
For patients under 65–70 years of age with good organ function (particularly kidney and heart), early ASCT after induction therapy is the standard of care for newly diagnosed multiple myeloma. Clinical guidelines from the National Institutes of Health (NIH) and major haematology societies consistently support upfront ASCT in eligible patients, citing significantly improved progression-free survival compared to chemotherapy alone.
Transplant works best when the myeloma burden has already been reduced by induction chemotherapy. Patients who achieve a very good partial response (VGPR) or complete response (CR) before transplant tend to have the best outcomes. If induction fails to produce a response, the transplant team may switch regimens before proceeding.
Some patients who were initially managed without a transplant — either by choice or because they were borderline eligible — may be offered a salvage ASCT at first relapse. This is particularly relevant if the patient responds well to second-line therapy and has adequate stem cell reserves collected earlier.
In high-risk myeloma — defined by cytogenetic abnormalities such as del(17p), t(4;14), or t(14;16) — some centres perform a tandem (double) autologous transplant, where two sequential transplants are performed within 6 months. Evidence suggests this approach may improve outcomes in this subgroup, though it is not universally adopted.
In some cases — particularly for older patients or those with comorbidities — the transplant team may recommend upfront stem cell collection but deferred transplant. The cells are stored, and the transplant is performed at first relapse. This preserves the option while avoiding immediate transplant-related toxicity.
Transplant eligibility is assessed carefully. Patients may not be suitable candidates if they have:
Significant heart failure or recent cardiac events
Severe renal impairment (though mild-to-moderate CKD is not an absolute contraindication)
Active, uncontrolled infection
Very advanced age combined with frailty or poor performance status
Myeloma that has not responded to any induction regimen
For patients who are not transplant-eligible, modern non-transplant regimens — including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies like daratumumab — have significantly improved outcomes. The oncology specialists at Apex Hospitals tailor treatment plans to each patient's biology, fitness, and goals of care.
Recovery from ASCT typically takes 3–6 months. Most patients are hospitalised for 3–4 weeks during the engraftment phase. After discharge, regular follow-up is essential to monitor for:
Minimal residual disease (MRD) status — assessed by bone marrow biopsy or flow cytometry
Maintenance therapy — lenalidomide maintenance post-transplant has been shown to extend progression-free survival and is now standard in many protocols
Infection surveillance — the immune system takes 6–12 months to fully reconstitute
Bone health — bisphosphonates or denosumab are continued to protect against skeletal events
Physiotherapy and nutritional rehabilitation play an important role in recovery. Apex Hospitals offers integrated physiotherapy and rehabilitation services as well as dietetics and nutrition support to help patients regain strength after transplant.
ASCT does not cure multiple myeloma in most patients, but it significantly deepens remission and extends the period before relapse. Key outcome benchmarks include:
Median progression-free survival after ASCT: 3–5 years with modern induction and maintenance
Complete response (CR) rates post-transplant: 40–60% with VRd induction
MRD negativity — the deepest measurable response — is associated with the longest remissions
Transplant-related mortality at experienced centres: less than 2–3%
Advances in novel agents — including CAR-T cell therapy and bispecific antibodies — are now being integrated into post-transplant strategies, offering new hope for patients who relapse. The critical care and ICU infrastructure at Apex Hospitals, including ECMO capability and a dedicated Cardiac ICU, ensures that high-risk transplant patients are supported through any complications.
Patients in Rajasthan no longer need to travel to Delhi or Mumbai for bone marrow transplant care. Apex Hospitals in Jaipur — NABH accredited and operating since 1994 — provides a comprehensive haemato-oncology programme with the infrastructure to support autologous transplant protocols. The hospital is empanelled under Ayushman Bharat, making treatment accessible to a wider patient population.
The hospital's transplant programme in Jaipur is supported by on-site CT, MRI, and emergency labs, a dedicated dialysis unit for patients with renal complications, and a 24×7 HOPE Tele-ICU Command Centre that connects 18 partner sites across Rajasthan — ensuring continuity of specialist oversight even after discharge.
For patients with concurrent kidney involvement — a common complication in myeloma — the nephrology team at Apex Hospitals works closely with the haemato-oncology unit to manage renal function throughout the transplant journey.
If you or a family member has been diagnosed with multiple myeloma and want to understand whether a stem cell transplant is appropriate, speaking with a specialist early — ideally before starting induction chemotherapy — gives you the most options. You can consult the specialist doctors at Apex Hospitals or reach the Malviya Nagar branch directly at 098290 30011.
They are closely related. In modern practice, stem cells for myeloma transplants are collected from the bloodstream (peripheral blood stem cells) rather than directly from the bone marrow. The term "bone marrow transplant" (BMT) is still widely used, but peripheral blood stem cell transplant (PBSCT) is the more precise term for most myeloma procedures today.
Transplant is most commonly offered at diagnosis (after induction therapy) for eligible patients. It can also be considered at first relapse as a salvage strategy. The decision is based on the patient's response to treatment, fitness, and disease biology — not stage alone.
Most patients are hospitalised for approximately 3–4 weeks — from the start of conditioning chemotherapy through engraftment. After discharge, close outpatient follow-up continues for several months.
Age alone is not a disqualifying factor. Fit patients in their late 60s or even early 70s may be considered for transplant after careful assessment of organ function and performance status. Reduced-intensity conditioning protocols are sometimes used to lower toxicity in older patients.
The cost of autologous stem cell transplant in India varies by centre and patient complexity. It is significantly lower than in Western countries, making India a destination for medical tourism in this area. Apex Hospitals accepts Ayushman Bharat and major insurance/TPA schemes — contact the hospital directly for a personalised cost estimate.
For most patients, myeloma eventually relapses after transplant. However, the depth and duration of remission achieved post-transplant is typically greater than with chemotherapy alone. Maintenance therapy with lenalidomide after transplant has been shown to delay relapse. At relapse, further treatment options — including novel agents and clinical trials — remain available.
Our haemato-oncology specialists at Apex Hospitals, Jaipur are here to help you understand your options and build a personalised treatment plan.
Download Our App
Powered By Docfyn
